These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1453214)

  • 1. Suramin: is adaptive control necessary?
    Kobayashi K; Vokes EE; Stefansson K; Janisch L; Vogelzang NJ; Berezin F; Ratain MJ
    J Clin Oncol; 1992 Dec; 10(12):1984-5; author reply 1985-6. PubMed ID: 1453214
    [No Abstract]   [Full Text] [Related]  

  • 2. Adaptive control with feedback of suramin using intermittent infusions.
    Figg WD; Stevens JA; Cooper MR
    J Clin Oncol; 1994 Jul; 12(7):1523-4. PubMed ID: 8021743
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
    Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
    J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
    Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
    J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
    Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
    J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive control with feedback strategies for suramin dosing.
    Cooper MR; Lieberman R; La Rocca RV; Gernt PR; Weinberger MS; Headlee DJ; Kohler DR; Goldspiel BR; Peck CC; Myers CE
    Clin Pharmacol Ther; 1992 Jul; 52(1):11-23. PubMed ID: 1623689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
    Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
    J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
    Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suramin.
    Eisenberger MA; Reyno LM
    Cancer Treat Rev; 1994 Jul; 20(3):259-73. PubMed ID: 8020006
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
    Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
    J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
    Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaphylactoid reaction with suramin.
    Thibault A; Figg WD; Cooper MR; Prindiville SA; Sartor AO; Headlee DJ; Myers CE
    Pharmacotherapy; 1993; 13(6):656-7. PubMed ID: 8302692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
    Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
    J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
    Bitton RJ; Figg WD; Venzon DJ; Dalakas MC; Bowden C; Headlee D; Reed E; Myers CE; Cooper MR
    J Clin Oncol; 1995 Sep; 13(9):2223-9. PubMed ID: 7666080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
    Kobayashi K; Vokes EE; Vogelzang NJ; Janisch L; Soliven B; Ratain MJ
    J Clin Oncol; 1996 Sep; 14(9):2622-3. PubMed ID: 8823342
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
    Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
    Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suramin and prostate cancer: where do we go from here?
    Clark JW; Chabner BA
    J Clin Oncol; 1995 Sep; 13(9):2155-7. PubMed ID: 7666073
    [No Abstract]   [Full Text] [Related]  

  • 18. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
    Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
    J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
    Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
    J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data modifications to phase I study of suramin.
    Kobayashi K; Vokes EE; Vogelzang NJ; Ratain MJ
    J Clin Oncol; 1996 Sep; 14(9):2623-4. PubMed ID: 8823343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.